2. Membrane Transporter/Ion Channel Autophagy Neuronal Signaling Cell Cycle/DNA Damage Epigenetics
  3. Sodium Channel Autophagy Mitophagy Potassium Channel Calcium Channel HDAC
  4. Carbamazepine

Carbamazepine is an orally active pressure-sensitive sodium ion channel blocker with an IC50 of 131 μM. Carbamazepine blocks voltage gated Na+, Ca2+, and K+ channels, and is also a HDAC inhibitor (IC50: 2 μM). Carbamazepine is an anticonvulsant and can be used for research of epilepsy and neuropathic pain.

Para uso exclusivo en investigación. No vendemos a pacientes.

No. CAS : 298-46-4

Tamaño Precio Stock Cantidad
Muestra gratis (0.1 - 0.2 mg)   Solicite ahora  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 En stock
Solution
10 mM * 1 mL in DMSO En stock
Solid
100 mg En stock
500 mg En stock
1 g   Obtener un presupuesto  
5 g   Obtener un presupuesto  

* Seleccione Cantidad antes de agregar artículos.

This product is a controlled substance and not for sale in your territory.

Revisión del cliente

Based on 17 publication(s) in Google Scholar

Other Forms of Carbamazepine:

Carbamazepine Related Antibodies

Top Publications Citing Use of Products

    Carbamazepine purchased from MedChemExpress. Usage Cited in: Adv Funct Mater. 2025 Nov 3.

    Carbamazepine (CBZ; 1–50 µg/mL; 24 h) exhibited extremely low cytotoxicity in SH-SY5Y cells at concentrations below 12.5 µg/mL. However, at a concentration of 50 µg/mL, cell viability decreased significantly to below 80%.

    Carbamazepine purchased from MedChemExpress. Usage Cited in: World J Methodol. 2025 Jun 20;15(2):99580.  [Abstract]

    Carbamazepine (4–8 mg/kg) inhibited tonic hindlimb extension (THLE) in mice, demonstrating a significant anticonvulsant protective effect.

    Carbamazepine purchased from MedChemExpress. Usage Cited in: J Pharm Anal. 2025 Jan;15(1):101132.  [Abstract]

    Carbamazepine (CBZ, 10 μM) exhibited an inhibition rate of 39.00% on NaV1.7 channels and 28.02% on NaV1.8 channels.

    Carbamazepine purchased from MedChemExpress. Usage Cited in: Autophagy. 2023 Jan;19(1):324-337.  [Abstract]

    Survival curves of zebrafish embryos infected with A. fumigatus ∆Ku80 and exposed via waterborne treatment to 100 μM Carbamazepine (Mtor-independent induction of autophagy via the inositol pathway), or DMSO as a vehicle control at the same v:v. The results showed that the autophagy-inducing treatment (Carbamazepine) consistently enhanced​ host survival during A. fumigatus infection compared to the DMSO control.

    Carbamazepine purchased from MedChemExpress. Usage Cited in: Pharmacol Res Perspect. 2021 Oct;9(5):e00879.  [Abstract]

    Pharmacokinetic parameters of the 14 compounds following an IV single bolus (n = 3; mean ± SD) (n = 3, mean ± SD).

    Ver todos los productos específicos de isoformas Sodium Channel:

    Ver todas las isoformas
    Nav1.1 Nav1.2 Nav1.3 Nav1.4 Nav1.5 Nav1.6 Nav1.7 Nav1.8 Nav1.9

    Ver todos los productos específicos de isoformas Calcium Channel:

    Ver todas las isoformas
    N-type calcium channel L-type calcium channel P/Q-type calcium channel T-type calcium channel Calcium Channel

    Ver todos los productos específicos de isoformas HDAC:

    Ver todas las isoformas
    HDAC HDAC1 HDAC2 HDAC3 HDAC4 HDAC5 HDAC6 HDAC7 HDAC8 HDAC9 HDAC10 HDAC11 HD1 HD2

    • Actividad biológica

    • Pureza y Documentación

    • Referencias

    • Revisión del cliente

    Descripciòn

    Carbamazepine is an orally active pressure-sensitive sodium ion channel blocker with an IC50 of 131 μM. Carbamazepine blocks voltage gated Na+, Ca2+, and K+ channels, and is also a HDAC inhibitor (IC50: 2 μM). Carbamazepine is an anticonvulsant and can be used for research of epilepsy and neuropathic pain[1][2][3].

    Cellular Effect
    Cell Line Type Value Description References
    HEK293 IC50
    22 μM
    Compound: 2, carbamazepine
    Blockade of human Nav1.7 channel expressed in HEK293 cells by FRET assay
    Blockade of human Nav1.7 channel expressed in HEK293 cells by FRET assay
    		[PMID: 18243692]
    Hepatocyte EC50
    145 μM
    Compound: Carbamazepine
    Induction of CYP2B6 activity in human donor hepatocytes assessed as hydroxybupropion formation after 48 hrs by LC/MS method
    Induction of CYP2B6 activity in human donor hepatocytes assessed as hydroxybupropion formation after 48 hrs by LC/MS method
    		[PMID: 22815312]
    Hepatocyte EC50
    26 μM
    Compound: Carbamazepine
    Induction of CYP2B6 mRNA expression in human donor hepatocytes after 48 hrs by real-time PCR method
    Induction of CYP2B6 mRNA expression in human donor hepatocytes after 48 hrs by real-time PCR method
    		[PMID: 22815312]
    ScN2a EC50
    >10 μM
    Compound: Carbamazepine
    Half maximal inhibition of Prion protein PrPsc formation was assayed in ScN2a cells
    Half maximal inhibition of Prion protein PrPsc formation was assayed in ScN2a cells
    		[PMID: 12904059]
    Sf21 IC50
    >1000 μM
    Compound: Carbamazepine
    Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake
    Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake
    		[PMID: 21965623]
    Sf21 IC50
    >1000 μM
    Compound: Carbamazepine
    Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake
    Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake
    		[PMID: 21965623]
    In Vitro

    Carbamazepine (0-500 μM, 10 days) inhibits pre-adipocyte differentiation (10 days) and triglyceride accumulation (7 days) in 3T3-L1, 3T3-F442A and T37i cells[4].
    Carbamazepine (5-20 μM, 15 min before LPS) inhibits LPS-induced production of NO and iNOS protein, and phosphorylation of Akt in microglial (BV-2) cells[5].
    Carbamazepine (20 μM, 15 min before LPS) inhibits LPS-induced COX-2 expression and TNF-α production in microglial (BV-2) cells[5].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Carbamazepine Related Antibodies

    Western Blot Analysis[4]

    Cell Line: 3T3-L1 pre-adipocytes
    Concentration: 0-500 μM
    Incubation Time: 10 days
    Result: Decreased PPAR-γ and C/EPB-α protein levels.
    Increased ERK 1/2 phosphorylation after a 10 min exposure, and also increased p38 MAPK phosphorylation.
    In Vivo

    Carbamazepine (250 mg/kg, p.o.) promotes liver regeneration and survival in partial hepatectomy (PHx) treated mice[6].
    Carbamazepine (0.25%-0.75% for ICR mice, 0.5% and 0.75% for C57bl/6 mice with, in food (w/w)) shows mood-stabilising effects in mice[7].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: 70% Partial hepatectomy treated mice[6]
    Dosage: 250 mg/kg
    Administration: p.o.
    Result: Recoverd liver to body weight ratio.
    Increased the number of BrdU-positive nuclei, Increased PCNA protein.
    Increased mRNA levels of ccne2 and ccna2.
    Ensayo clínico
    Peso molecular

    236.27

    Fòrmula

    C15H12N2O
    No. CAS
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    O=C(N1C2=CC=CC=C2C=CC3=CC=CC=C31)N
    Envío

    Room temperature in continental US; may vary elsewhere.
    Almacenamiento

    Store at room temperature 3 years

    In solvent -80°C 2 years
    -20°C 1 year
    Solvente y solubilidad
    In Vitro: 

    DMSO : 50 mg/mL (211.62 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    H2O : < 0.1 mg/mL (insoluble)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 4.2324 mL 21.1622 mL 42.3245 mL
    5 mM 0.8465 mL 4.2324 mL 8.4649 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

    • Calculadora de molaridad

    • Calculadora de dilución

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.5 mg/mL (10.58 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.5 mg/mL (10.58 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

    For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  50% PEG300    50% Saline

      Solubility: 25 mg/mL (105.81 mM); Clear solution; Need ultrasonic

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Pureza y Documentación

    Purity: 99.90%

    SDS (558 KB)

    COA (258 KB) LCMS (97 KB)

    Instrucciones de manejo (2659 KB)
    Referencias

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 4.2324 mL 21.1622 mL 42.3245 mL 105.8111 mL
    5 mM 0.8465 mL 4.2324 mL 8.4649 mL 21.1622 mL
    10 mM 0.4232 mL 2.1162 mL 4.2324 mL 10.5811 mL
    15 mM 0.2822 mL 1.4108 mL 2.8216 mL 7.0541 mL
    20 mM 0.2116 mL 1.0581 mL 2.1162 mL 5.2906 mL
    25 mM 0.1693 mL 0.8465 mL 1.6930 mL 4.2324 mL
    30 mM 0.1411 mL 0.7054 mL 1.4108 mL 3.5270 mL
    40 mM 0.1058 mL 0.5291 mL 1.0581 mL 2.6453 mL
    50 mM 0.0846 mL 0.4232 mL 0.8465 mL 2.1162 mL
    60 mM 0.0705 mL 0.3527 mL 0.7054 mL 1.7635 mL
    80 mM 0.0529 mL 0.2645 mL 0.5291 mL 1.3226 mL
    100 mM 0.0423 mL 0.2116 mL 0.4232 mL 1.0581 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Carbamazepine Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Carbamazepine298-46-4CBZ NSC 169864NSC169864NSC 169864NSC-169864Sodium ChannelAutophagyMitophagyPotassium ChannelCalcium ChannelHDACNa channelsNa+ channelsMitochondrial AutophagyKcsACa2+ channelsCa channelsHistone deacetylasesepilepsyneuropathic painanticonvulsantInhibitorinhibitorinhibit

    Productos vistos recientemente:

    Consulta en línea

    Your information is safe with us. * Required Fields.

    Nombre del producto

    		  

    Requested Quantity *

    Nombre del solicitante *

    		 

    Saludo

    Direcciòn del E-mail *

    		 

    Número de teléfono *

    Department

    		 

    Nombre de la Organizaciòn *

    City

    Provincia

    Country or Region *

    		      

    Observaciones

    Consulta para venta a granel

    Inquiry Information

    Nombre del producto:
    Carbamazepine
    Cat. No.:
    HY-B0246
    Cantidad:
    MCE Japan Authorized Agent:

    Revisión del cliente

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Nombre del producto

    		  

    Lot #

    Nombre del solicitante *

    		 

    Direcciòn del E-mail *

    Número de teléfono

    		 

    Department *

    Nombre de la Organizaciòn *

    		 

    Country or Region *

    Observaciones

    SAFETY DATA SHEET (SDS)

    English - EN (558 KB) Français - FR (558 KB) Deutsch - DE (558 KB) Norwegian - NO (558 KB) Español - ES (558 KB) Swedish - SV (558 KB) Italian - IT (558 KB) Korean - KR (558 KB) Portuguese - PT (558 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.